RT @OncBrothers
#OncTwitter #MedTwitter #LCSM #bcsm #gism #gusm

How are you rationing Carbo?
- Any creative regimens for #BreastCancer (#TNBC or #HER2 pts in neoadj settings)?
- For Cis ineligible small cell #LungCancer? PDL-1 negative mNSCLC?
- Head & Neck Pts?
- How are you sharing this… https://twitter.com/i/web/status/1653848101679931393

RT @gvansant1
#ADC #HER2 targeted therapy https://twitter.com/johnebbenmdphd/status/1624136276495503363

RT @TumorBoardTues
#TumorBoardTuesday

🔬🧬@DrTeplinksy took us through paradigm-shifting therapy in #HER2 low #metastaticbreastcancer.

➡️Here’s the Case 🎀

👉 🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt

CME eval🔗: http://integrityce.com/tbteval

#TumorBoardTuesday

🔬🧬@DrTeplinksy took us through paradigm-shifting therapy in #HER2 low #metastaticbreastcancer.

➡️Here’s the Case 🎀

👉 🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: http://integrityce.com/tbt

CME eval🔗: http://integrityce.com/tbteval

Thank you @drteplinsky for an engaging #TumorBoardTuesday! Exciting to see how the treatment of #HER2 low disease is changing.

Watch for a special Friday ed of wrap up. To get ready, try your 👋🏼at the ❓s for free #CME!

---
RT @drteplinsky
#PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval🔗 http://integrityce.com/tbtEval

🤔@drteplinsky taught us progress of HER2+ low #breastcancer
🤨What would U pick for 60y👩🏻
ER+/PR-/HER2-low mBC
recent …
https://twitter.com/drteplinsky/status/1623139634694787073

RT @TumorBoardTues
Thank you @Drteplinsky for an engaging #TumorBoardTuesday! Exciting to see how the treatment of #HER2 low disease is changing.

Watch for a special Friday ed of wrap up. To get ready, try your 👋🏼at the ❓s for free #CME!

https://twitter.com/drteplinsky/status/1623139634694787073?s=46&t=b_4kLKpzDqR_yXAEafFDZw

RT @DrGattiMays@twitter.com

Phase 1 trial by @aszim13@twitter.com that TDM-1 + temozolamide may reduce risk of new brain metastases in patients with metastatic HER2+ with known CNS metastases #bcsm #Brainmets #HER2 👏👏 https://twitter.com/filippomontemu1/status/1619602480073150465

🐦🔗: https://twitter.com/DrGattiMays/status/1619680319082463232

RT @BasileWicky
Zero-shot generation of antibody variants against #Her2 yields dozen of designs with double-digit nM affinity (on par with clinical standard #Trastuzumab) and significant sequence diversity
@abscibio
https://www.biorxiv.org/content/10.1101/2023.01.08.523187v1

RT @Sameh_VuMedi@twitter.com

Dr. Erika Hamilton @ErikaHamilton9@twitter.com @SarahCannonDocs@twitter.com discussing Dose-Expansion Study DESTINY-Breast07: T-DXd as Monotherapy or Combined With #Pertuzumab in pts With Metastatic #HER2+ #breastcancer from #SABCS22 #bcsm #mBC #VuMedi #OncTwitter #MedTwitter

https://bit.ly/SABCS22TDX

🐦🔗: https://twitter.com/Sameh_VuMedi/status/1605960936535117828

"In the last 20 years, numerous other HER2-targeted therapies have proven successful in the metastatic, adjuvant and neoadjuvant settings, including another monoclonal antibody — pertuzumab — three separate tyrosine kinase inhibitors — lapatinib, neratinib, and tucatinib — and two antibody drug conjugates (ADCs) — ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan (TDx-D)."

#BreastCancer #her2

https://www.jci.org/articles/view/166384

#ATEMPT also looked at "right sizing" treatment w/ T-DM1 for small #HER2 #bcsm w/ similar fantastic outcomes.

📣ATEMPT2.0 will examine 6 months of T-DM1 as 1 yr was actually a bit harder to tolerate than we expected

#SABCS22 @OncoAlert@twitter.com

@PTarantinoMD@twitter.com @stolaney1@twitter.com

Sara Hurvitz discusses #APT a "right size" trial giving just paclitaxel + trastuzumab adjuvantly for #HER2 #bcsm

🔹excellent outcomes at 10 yrs w/ relapse free survival over 95% 👏

🔸HER2DX score looks to help us pick who may be appropriate as well

#SABCS22 @OncoAlert@twitter.com

Martine Piccart reminds us of #PHERgain re: these #HER2 abstracts- for those who had a SUV decrease of 40% of more at 6 weeks had high pCR rates.

MRIs also quite good at predicting

Should everyone get an early imaging look with a chance to de-escalate?

#SABCS22 @OncoAlert@twitter.com

Unclear that #HER2 low is a different entity (IMO I think not),

....but regardless, increasing body of evidence that patients with low expression actually have longer OS and better prognosis.

#SABCS22 @OncoAlert@twitter.com

Webinar: “Identifying HER2-low expression – A pathologist led slide review”
Dr Jim Richter (Roche Diagnostics)
December 14 at 2 pm ET / 11 am PT.
https://thepathologist.videomarketingplatform.co/identifying-her2-low-expression-a

Hosted by The Pathologist, this event aims to highlight the importance of each level of #HER2 expression. This is supported by an image review and case scoring session for both select and difficult cases.
#breastcancer